Tag: CLRB

Blue Horseshoe Stocks: FL, CNXS Recaps & More

Franchise Holding International, Inc. FNHI

On Friday morning, we were giving our readers an update on the stellar performance of FNHI since we’d first called it back on the 8th. subsequent to which time, the stock was trading at a low of .0061.

Not only did FNHI follow it up with a solid intraday pop, but also extended our total observed range in just over three weeks by a significant margin.

Friday, FNHI traded from 0265-.0449 for an intraday push of 69% That new high, measured from our witnessed low, comes out to an overall upswing of 636%

The stock also closed with strength at .0421, holding most of its daily advance, so we’ll be watching it this morning as we prepare to kick off a new trading week.

Connexus Corp. CNXS

Speaking of big movers, our tag of CNXS in Friday’s report came just in the nick of time for us to catch a fantastic intraday performance.

The stock traded up from a low of .0051, cracked through the penny barrier, and reached as high as .0159, for a whopping run of 212% on the day!

That performance marked the third straight session of higher highs and higher lows, so we’re definitely going to be on the lookout for a possible continuation of that trend. Ideally, we’d like to see CNXS hold support at or above Thursday’s swing high of .0092 on any pullbacks.

Foot Locker, Inc. FL – Options Update

We also need to bring readers up to speed on the excellent  post-earnings options idea we formulated on Friday for Foot Locker, the FL 03/17 $70-75 Calls.

Those contracts provided daytraders with some cherry opportunities for quick gains with FL’s bullish intraday run from 70.37 to 75.37. The potential profits were as follows:

$70 Calls – Range: 2.00-5.00 – Max Gain: 150%
$72.50 Calls – Range: .95-3.60 – Max Gain: 279%
$75 Calls – Range: .26-2.00 – Max Gain: 669%

Special Note on Bitcoin

Prior to last week, the all time high for Bitcoin was $1160, last week that high was broken, and has been making higher highs since.

Winklevoss Bitcoin Trust ETF (Pending:COIN) is subject to approval. Essentially, if the SEC raises no issues by the end of the comment period, the ETF can move forward unhindered. It has caused an increased interest in the space, and as a result, we’ve got our eyes on stocks like the above-mentioned CNXS, along with others like BTSC and GAHC

Extended Watchlist:
CLRB, CEMP, USRM, ABHI, AMFE, IBRC

Blue Horseshoe Stocks: MYHI Recap & Other Updates

Mountain High Acquisitions Corp. MYHI

Our first order of business this morning is to review the recent activity in MYHI, another cannabis stock amid the huge selection we’re constantly tracking. We’ve been all over this play in the month of January, beginning with the first report of the calendar year, and appearing routinely since then, all while maintaining a general uptrend.

Our witnessed low came in the session immediately following that first premarket report of 2017 back on January 3rd, at .09. Over the course of this month, MYHI has streaked skyward with some very impressive multi-day surges, the latest of which led to a new high yesterday.

We also included MYHI in yesterday’s premarket report, so for those readers who haven’t been with us long enough to have witnessed the full story on this play, single-session gains of a significant magnitude were also available. MYHI ran from a low of .5616 to its new high of .90 on heavy volume, an intraday push of 63%

The high mark represented an overall upswing of 900% from our observed low on the 3rd, exactly three weeks ago, so huge cheers are in order for anyone who has been along for this fantastic ride!

Other Pot Stock Updates

Speaking of the marijuana space, which has definitely been a prime area of focus for us in recent months especially, we had a couple of our other running cannabis interests that were included in yesterday’s premarket report end up performing well on the day.

We had Rocky Mountain High Brands, Inc. RMHB trade up from .13 to .16 for a modest 23% intraday push, reaching overall gains of 74% from the .092 low we observed after including the stock in Friday’s report.

There was also Hemp, Inc. HEMP, which was another one we put in the first report of the year and have been tracking ever since. It spiked 16% intraday yesterday from .0467 to .054, and from our witnessed low of .03, a total rise of 80%

Cellectar Biosciences, Inc. CLRB

CLRB is hitting our scanner in the premarket today, gapping up to the tune of 15% and showing all the symptoms of a solid bottom-bouncer.

There is a gap on the chart between approximately 1.80 and 2.20. We would like to see the stock maintain support above the 50DMA(1.50) and potentially make a run to fill that gap.

VanEck Vectors Gold Miners ETF (GDX) – Options Reminder

Just a quick reminder on our options ideas from yesterday’s report; the GDX 02/10 $24-25.50 Calls which we put on extended watch, made some decent progress on the first day, producing gains ranging between 20-40%

We’ll continue to track these ideas for the possibility of further increases for as long as gold itself can maintain its overall uptrend. In this case, that would likely mean holding support above the $1200/oz mark.

Extended Watchlist
PURA, MYDX, UAMM, PKTX, ISBG, ICNB, MIHI(News)

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD